Clinical Trial Update: A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer [Phase 2]

View source ↗

Summary

A Phase II trial evaluating Pyrotinib in combination with the CDK4/6 inhibitor SHR6390 in patients with trastuzumab-treated advanced HER2-positive breast cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pyrotinib (pyrotinib)
• SHR6390 (SHR6390)

Snippet

Sponsor: Jinming Yu | Conditions: Metastatic Breast Cancer, HER2-positive Breast Cancer | Phase 2 | Status: UNKNOWN